Selpercatinib

Last Updated: 04/28/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 467 publications

Erratum to Acute β-cell failure induced by selpercatinib in RET fusion-positive non-small cell lung cancer: A case report [Respir. Med. Case Rep. 59 (2026) 102372].

Erratum to Acute β-cell failure induced by selpercatinib in RET fusion-positive non-small cell lung cancer: A case report [Respir. Med. Case Rep. 59 (2026) 102372].

Journal: Respiratory medicine case reports

Published: March 30, 2026

Molecular and Clinical Profile of a RET-Rearranged Colorectal Cancer With Prolonged Response to Platinum Therapy and Subsequent Targeted Treatment With Selpercatinib.

Molecular and Clinical Profile of a RET-Rearranged Colorectal Cancer With Prolonged Response to Platinum Therapy and Subsequent Targeted Treatment With Selpercatinib.

Journal: JCO precision oncology

Published: March 25, 2026

Metastatic Medullary Thyroid Carcinoma in Multiple Endocrine Neoplasia Type 2B (MEN 2B) With RET M918T Mutation: Challenges in Long-Term Management and Targeted Therapy.

Metastatic Medullary Thyroid Carcinoma in Multiple Endocrine Neoplasia Type 2B (MEN 2B) With RET M918T Mutation: Challenges in Long-Term Management and Targeted Therapy.

Journal: Cureus

Published: February 25, 2026

Two Cases of Papillary Thyroid Carcinoma With QTc Prolongation During Selpercatinib Administration: A Case Report.

Two Cases of Papillary Thyroid Carcinoma With QTc Prolongation During Selpercatinib Administration: A Case Report.

Journal: Cureus

Published: February 18, 2026

Safety evaluation of selective RET inhibitors in patients with lung cancer: a real-world pharmacovigilance study.

Safety evaluation of selective RET inhibitors in patients with lung cancer: a real-world pharmacovigilance study.

Journal: Tumori

Published: February 06, 2026

Molecular pathogenesis and therapeutic advances in RET fusion-positive papillary thyroid carcinoma.

Molecular pathogenesis and therapeutic advances in RET fusion-positive papillary thyroid carcinoma.

Journal: Pathology, research and practice

Published: January 21, 2026

Acquired CCDC6-RET Fusion After First-Line Osimertinib in Epidermal Growth Factor Receptor (EGFR)-Mutant Lung Adenocarcinoma: A Case Report.

Acquired CCDC6-RET Fusion After First-Line Osimertinib in Epidermal Growth Factor Receptor (EGFR)-Mutant Lung Adenocarcinoma: A Case Report.

Journal: Cureus

Published: January 14, 2026

Central nervous system effectiveness of selpercatinib retreatment in heavily pretreated NSCLC patient with RET rearrangement: A case report.

Central nervous system effectiveness of selpercatinib retreatment in heavily pretreated NSCLC patient with RET rearrangement: A case report.

Journal: Tumori

Published: January 12, 2026

Loss of WT1 Drives Adaptive Plasticity in CCDC6-RET Selpercatinib-Resistant Papillary Thyroid Cancer.

Loss of WT1 Drives Adaptive Plasticity in CCDC6-RET Selpercatinib-Resistant Papillary Thyroid Cancer.

Journal: Current issues in molecular biology

Published: January 05, 2026

Reversal of Paraneoplastic Non-Bacterial Thrombotic Endocarditis with Heparin and Targeted Cancer Therapy: A Case Report.

Reversal of Paraneoplastic Non-Bacterial Thrombotic Endocarditis with Heparin and Targeted Cancer Therapy: A Case Report.

Journal: Reports (MDPI)

Published: December 31, 2025

Retreatment with First-Generation Selective RET Inhibitors in RET-Rearranged NSCLC Pretreated with Selpercatinib or Pralsetinib - Results from the RET-MAP Registry.

Retreatment with First-Generation Selective RET Inhibitors in RET-Rearranged NSCLC Pretreated with Selpercatinib or Pralsetinib - Results from the RET-MAP Registry.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: December 23, 2025

Selpercatinib for RET-positive advanced pancreatic cancer detected by liquid biopsy: a case-based insight.

Selpercatinib for RET-positive advanced pancreatic cancer detected by liquid biopsy: a case-based insight.

Journal: Pharmacogenomics

Published: December 15, 2025

Showing 1-12 of 467

Last Updated: 04/28/2026